Renaissance Technologies (RenTech)'s KURA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.58 M shares of Kura Oncology, Inc. (KURA) worth $12.87 M, representing 0.02% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in KURA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 965,256 shares. Largest reduction occurred in Q1 2026, reducing 247,998 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Kura Oncology (KURA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Kura Oncology (KURA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -247,998 | Reduce 13.55% | 1.58 M | $8.13 |
| Q4 2025 | +965,256 | Add 111.55% | 1.83 M | $10.39 |
| Q3 2025 | -191,700 | Reduce 18.14% | 865,310 | $8.85 |
| Q2 2025 | +524,400 | Add 98.46% | 1.06 M | $5.77 |
| Q1 2025 | -65,200 | Reduce 10.91% | 532,610 | $6.60 |
| Q4 2024 | +491,700 | Add 463.39% | 597,810 | $8.71 |
| Q3 2024 | -15,090 | Reduce 12.45% | 106,110 | $19.54 |
| Q2 2024 | -119,000 | Reduce 49.54% | 121,200 | $20.59 |
| Q1 2024 | -37,900 | Reduce 13.63% | 240,200 | $21.33 |
| Q4 2023 | +162,500 | Add 140.57% | 278,100 | $14.38 |
| Q3 2023 | -72,500 | Reduce 38.54% | 115,600 | $9.12 |
| Q2 2023 | +171,500 | Add 1033.13% | 188,100 | $0.01 |
| Q1 2023 | +16,600 | New Buy | 16,600 | $0.01 |
| Q4 2022 | -124,500 | Sold Out | 0 | $0.00 |
| Q3 2022 | -20,500 | Reduce 14.14% | 124,500 | $13.66 |
| Q2 2022 | -133,400 | Reduce 47.92% | 145,000 | $18.33 |
| Q1 2022 | +210,700 | Add 311.23% | 278,400 | $16.08 |
| Q4 2021 | -106,400 | Reduce 61.11% | 67,700 | $14.00 |
| Q3 2021 | -128,100 | Reduce 42.39% | 174,100 | $18.73 |
| Q2 2021 | +302,200 | New Buy | 302,200 | $20.85 |
| Q2 2020 | -85,271 | Sold Out | 0 | $0.00 |
| Q1 2020 | +85,271 | New Buy | 85,271 | $9.94 |
| Q1 2018 | -89,294 | Sold Out | 0 | $0.00 |
| Q4 2017 | -177,106 | Reduce 66.48% | 89,294 | $15.30 |
| Q3 2017 | +176,400 | Add 196.00% | 266,400 | $14.95 |
| Q2 2017 | +10,800 | Add 13.64% | 90,000 | $9.30 |
| Q1 2017 | +48,600 | Add 158.82% | 79,200 | $8.80 |
| Q4 2016 | +6,200 | Add 25.41% | 30,600 | $5.92 |
| Q3 2016 | +11,100 | Add 83.46% | 24,400 | $6.27 |
| Q2 2016 | +13,300 | New Buy | 13,300 | $2.71 |
Renaissance Technologies (RenTech)'s Kura Oncology Investment FAQs
Renaissance Technologies (RenTech) first purchased Kura Oncology, Inc. (KURA) in Q2 2016, acquiring 13,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Kura Oncology, Inc. (KURA) for 30 quarters since Q2 2016.
Renaissance Technologies (RenTech)'s largest addition to Kura Oncology, Inc. (KURA) was in Q4 2025, adding 1,830,566 shares worth $19.02 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,582,568 shares of Kura Oncology, Inc. (KURA), valued at approximately $12.87 M.
As of the Q1 2026 filing, Kura Oncology, Inc. (KURA) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Kura Oncology, Inc. (KURA) was 1,830,566 shares, as reported at the end of Q4 2025.